Cargando…

Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management

Nonalcoholic fatty liver disease (NAFLD) accounts for most cases of chronic liver disease worldwide, with an estimated global prevalence of approximately 25% and ranges from simple steatosis to nonalcoholic steatohepatitis and cirrhosis. NAFLD is strongly connected to metabolic syndrome, and for man...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chrysavgis, Lampros, Ztriva, Eleftheria, Protopapas, Adonis, Tziomalos, Konstantinos, Cholongitas, Evangelos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673972/ https://www.ncbi.nlm.nih.gov/pubmed/33268944 http://dx.doi.org/10.3748/wjg.v26.i42.6514

Ejemplares similares

Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no?
por: Protopapas, Adonis A., et al.
Publicado: (2021)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
por: Sofogianni, Areti, et al.
Publicado: (2020)

Frailty in metabolic syndrome, focusing on nonalcoholic fatty liver disease
por: Karakousis, Nikolaos D., et al.
Publicado: (2022)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link
por: Chrysavgis, Lampros, et al.
Publicado: (2022)

Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?
por: Tsankof, Alexandra, et al.
Publicado: (2022)

Hepatic Fibrosis Is a Risk Factor for Greater Severity and Worse Outcome of Acute Ischemic Stroke
por: Ztriva, Eleftheria, et al.
Publicado: (2022)

Acute Severe Hepatitis of Unknown Origin in Children Across the World: A 2022 Source of Concern
por: Chrysavgis, Lampros, et al.
Publicado: (2022)

Significance of Circulating Cell-Free DNA Species in Non-Alcoholic Fatty Liver Disease
por: Chrysavgis, Lampros, et al.
Publicado: (2021)

Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
por: Kontana, Anastasia, et al.
Publicado: (2019)

Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
por: Han, Eugene, et al.
Publicado: (2023)

Considerations for management of patients with diabetes mellitus and acute COVID-19
por: Mougakou, Efterpi, et al.
Publicado: (2022)

Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease
por: Kim, Yuna, et al.
Publicado: (2022)

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
por: Chun, Ho Soo, et al.
Publicado: (2023)

Combination therapies in nonalcoholic fatty liver disease using antidiabetic and disease-specific drugs
por: Koureta, Evgenia, et al.
Publicado: (2023)

Associations between nonalcoholic fatty liver disease and ischemic stroke
por: Alkagiet, Stelina, et al.
Publicado: (2018)

Lean nonalcoholic fatty liver disease and sarcopenia
por: Chen, Milian, et al.
Publicado: (2023)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2023)

Drug-Induced Liver Injury in Hospitalized Patients during SARS-CoV-2 Infection
por: Karlafti, Eleni, et al.
Publicado: (2022)

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?
por: Jang, Heejoon, et al.
Publicado: (2023)

Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects
por: Yun, Yeojun, et al.
Publicado: (2019)

Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
por: Neokosmidis, Georgios, et al.
Publicado: (2021)

Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease
por: Iritani, Soichi, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease
por: Ishido, Shun, et al.
Publicado: (2023)

Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease
por: Jiang, Yuanye, et al.
Publicado: (2023)

Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China
por: Lan, Yanqi, et al.
Publicado: (2022)

Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis
por: Cholongitas, Evangelos, et al.
Publicado: (2021)

Aspartate aminotransferase-to-platelet ratio index can predict the outcome in patients with stable decompensated cirrhosis
por: Oikonomou, Theodora, et al.
Publicado: (2023)

Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories
por: Kantartzis, Konstantinos, et al.
Publicado: (2023)

Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease
por: Park, Huiyul, et al.
Publicado: (2023)

Fatty liver in lean patients: is it a different disease?
por: Verdelho Machado, Mariana, et al.
Publicado: (2012)

Significance of Circulating Cell-Free DNA Biomarkers in HBeAg-Negative Chronic Hepatitis B Virus Infection and Their Changes after Treatment Initiation
por: Karakousis, Nikolaos D., et al.
Publicado: (2023)

Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients
por: Hirose, Shunji, et al.
Publicado: (2020)

Diet and Lifestyle in Nonalcoholic Fatty Liver Disease
por: Martínez-Beamonte, Roberto, et al.
Publicado: (2020)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

Combination Therapies for Nonalcoholic Fatty Liver Disease
por: Makri, Evangelia S., et al.
Publicado: (2022)

Predictive Risk Factors of Nonalcoholic Fatty Liver Disease in a Lean Chinese Population
por: Liu, Lu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g9rpdb78vuh54979fclem6r9k5